International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-6 doi: 10.5281/zenodo.14213998
Original Research Article
Role of Serum Ferritin in Predicting Pregnancy Outcomes in Gestational Diabetes Mellitus
Published
Nov. 25, 2024
Abstract

Background: The role of serum ferritin in predicting pregnancy outcomes among women with gestational diabetes mellitus (GDM) remains incompletely understood.Objective: To evaluate the association between serum ferritin levels and adverse pregnancy outcomes in women with GDM. Methods: This prospective observational study included 126 pregnant women diagnosed with GDM. Serum ferritin levels were measured at diagnosis, and participants were followed until delivery. Maternal and neonatal outcomes were analyzed in relation to ferritin levels. Results: The mean serum ferritin level was 85.6 ± 42.3 ng/mL, with 19.9% of participants showing elevated levels (>150 ng/mL). Significant positive correlations were observed between ferritin levels and glycemic parameters (HOMA-IR: r=0.51, p<0.001). Women with elevated ferritin levels demonstrated higher rates of pregnancyinduced hypertension (24.0% vs 9.0%, p=0.042), preeclampsia (16.0% vs 5.6%, p=0.038), and cesarean delivery (56.0% vs 34.8%, p=0.045). Neonatal complications, including macrosomia (32.0% vs 13.5%, p=0.028) and NICU admission (24.0% vs 10.1%, p=0.035), were significantly higher in the high ferritin group. Conclusion: Elevated serum ferritin levels are associated with increased risk of adverse maternal and neonatal outcomes in GDM patients, suggesting its potential utility as a predictive biomarker.

Recommended Articles
Loading Image...
Volume-5, Issue-6
Citations
1867 Views
459 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved